Lawyers USA Your Business Partner

Propecia litigation picks up momentum 

By: Sylvia Hsieh
Published: April 4, 2013

Tags: Merck, Propecia, Proscar

Litigation over the hair loss drug Propecia has picked up momentum with over 400 lawsuits pending in state and federal courts.

Fosamax suit can’t proceed based on ‘sham’ issue 

Published: February 4, 2013

Tags: expert testimony, failure to warn, Fosamax, Merck, osteonecrosis, product liability

Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.

Suits against Merck over hair loss drugs surge forward 

Published: December 5, 2012

Tags: drug litigation, Merck, Propecia, Proscar

Since last year when the first lawsuits against Merck were filed over its hair loss drugs Propecia and Proscar, the number of suits has multiplied to approximately 1,000 cases in multidistrict litigation in U.S. District Court for the Eastern District of New York.

Fosamax litigation ready for next step in bellwether cases 

By: Correy Stephenson
Published: December 4, 2012

Tags: drug litigation, femur fracture, Fosamax, Merck, multidistrict litigation, osteonecrosis

Six years after the first Fosamax lawsuit was filed, litigation over the osteoporosis drug is about to start a new chapter.

The suits against Merck, the drug’s manufacturer, fall into two categories: plaintiffs alleging they suffer from osteonecrosis, or jaw damage, and those claiming they suffered a non-traumatic femur fracture as a result of taking the drug.

Merck settles suit over illegal Vioxx marketing 

Published: November 2, 2012

Tags: class action, false marketing, Merck, Missouri, prescription drugs, Vioxx, Vioxx class action

Merck & Co. has agreed to pay at least $39 million into a fund to settle a Missouri class action over the marketing of the anti-inflammatory drug Vioxx, according to a tentative settlement agreement. 

‘False’ sunscreen claims settled for $3 million to $10 million 

Published: September 27, 2012

Tags: false advertising, false claims, Merck, sunscreen

Merck & Co has agreed to pay between $3 million and $10 million to settle a nearly decade old class-action lawsuit that alleged the company made false claims about the benefits of its Coppertone sunscreen products.

Some birth control associated with increased blood clot risk 

Published: May 18, 2012

Tags: birth control, birth control litigation, birth control patch, blood clots, drug litigation, Johnson & Johnson, Merck, Nuvaring, Ortho-Evra, product liability

Women who use birth control patches like Ortho-Evra or contraceptive vaginal rings like NuvaRing have a heightened risk of blood clots, a new medical study has found.

Merck settles Vytorin shareholder class action suit 

Published: March 12, 2012

Tags: class action, Merck, Vytorin

Merck will pay $5.1 million in attorney fees and institute corporate reforms under the terms of a settlement of a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin.

Texas woman sues Merck over injuries caused by NuvaRing 

Published: February 2, 2012

Tags: deep-vein thrombosis, Merck, Nuvaring, product liability

A Texas woman claims in a $10 million lawsuit against Merck that she suffered deep-vein thrombosis as a result of using the NuvaRing birth control device.

Special master appointed to help settle Fosamax cases 

Published: December 7, 2011

Tags: Fosamax, Merck, osteonecrosis, osteoporosis

After mixed results in bellwether cases, and a recent string of defense verdicts, a special settlement master has been appointed to the Fosamax multidistrict litigation.